Neurotrophic Keratitis News and Research

RSS
FDA approves first drug for treatment of rare disease affecting the cornea

FDA approves first drug for treatment of rare disease affecting the cornea

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Dompé enters definitive agreement to acquire Anabasis

Dompé enters definitive agreement to acquire Anabasis

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

RegeneRx to initiate enrollment in RGN-259 Phase 2 trial for dry eye syndrome

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Anabasis, Scil Proteins enter license deal for rhNGF to treat eye diseases

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

RegeneRx Biopharmaceuticals prices underwritten public offering at $0.41 per unit

Data from RGN-259 study published in Archives of Ophthalmology

Data from RGN-259 study published in Archives of Ophthalmology

RegeneRx Biopharmaceuticals proposes common stock public offering

RegeneRx Biopharmaceuticals proposes common stock public offering

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.